Кто интересуется Спутником V? Кое-что сегодня выложили в Ланцет
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
The Lancet
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised…
This interim analysis of the phase 3 trial of Gam-COVID-Vac showed 91·6% efficacy
against COVID-19 and was well tolerated in a large cohort.
against COVID-19 and was well tolerated in a large cohort.